Robeco Institutional Asset Management B.V. Purchases 256,841 Shares of Royalty Pharma PLC $RPRX

Robeco Institutional Asset Management B.V. boosted its position in Royalty Pharma PLC (NASDAQ:RPRX) by 28.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,168,427 shares of the biopharmaceutical company’s stock after buying an additional 256,841 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Royalty Pharma were worth $68,189,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of RPRX. Bank of America Corp DE lifted its stake in shares of Royalty Pharma by 29.0% in the 1st quarter. Bank of America Corp DE now owns 3,495,846 shares of the biopharmaceutical company’s stock worth $167,696,000 after acquiring an additional 786,921 shares during the period. Amundi increased its stake in shares of Royalty Pharma by 15.3% during the first quarter. Amundi now owns 3,088,773 shares of the biopharmaceutical company’s stock worth $148,168,000 after acquiring an additional 409,394 shares during the period. Dorsey Asset Management LLC increased its stake in shares of Royalty Pharma by 0.8% during the first quarter. Dorsey Asset Management LLC now owns 2,276,570 shares of the biopharmaceutical company’s stock worth $109,207,000 after acquiring an additional 17,101 shares during the period. Hsbc Holdings PLC raised its holdings in Royalty Pharma by 2,562.2% during the first quarter. Hsbc Holdings PLC now owns 1,544,018 shares of the biopharmaceutical company’s stock worth $74,000,000 after purchasing an additional 1,486,020 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. raised its holdings in Royalty Pharma by 0.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,273,705 shares of the biopharmaceutical company’s stock worth $61,100,000 after purchasing an additional 5,661 shares in the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Royalty Pharma Stock Performance

Shares of RPRX opened at $63.75 on Friday. The company has a 50-day simple moving average of $59.72 and a 200-day simple moving average of $56.16. The company has a quick ratio of 2.80, a current ratio of 2.80 and a debt-to-equity ratio of 0.88. The company has a market capitalization of $36.66 billion, a PE ratio of 43.97, a P/E/G ratio of 1.70 and a beta of 0.42. Royalty Pharma PLC has a 52-week low of $35.92 and a 52-week high of $64.38.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.05. The firm had revenue of $674.14 million for the quarter, compared to the consensus estimate of $758.93 million. Royalty Pharma had a net margin of 32.14% and a return on equity of 30.01%. Equities research analysts predict that Royalty Pharma PLC will post 5.29 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a $0.2350 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $0.94 dividend on an annualized basis and a yield of 1.5%. Royalty Pharma’s dividend payout ratio (DPR) is 64.83%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on RPRX shares. Bank of America reissued a “buy” rating on shares of Royalty Pharma in a research note on Wednesday, August 5th. Weiss Ratings upgraded Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, September 14th. The Goldman Sachs Group restated a “buy” rating and issued a $66.00 price target on shares of Royalty Pharma in a research note on Thursday, August 6th. TD Cowen upped their price objective on Royalty Pharma from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Tuesday, September 8th. Finally, JPMorgan Chase & Co. increased their price objective on Royalty Pharma from $58.00 to $62.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $61.57.

Insider Buying and Selling

In other news, EVP Marshall Urist sold 4,126 shares of Royalty Pharma stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $57.10, for a total transaction of $235,594.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $58.53, for a total value of $5,853,000.00. Following the sale, the executive vice president directly owned 270,401 shares in the company, valued at $15,826,570.53. This trade represents a 27.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 208,252 shares of company stock valued at $12,324,407. Insiders own 18.84% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc (NASDAQ:RPRX) is a biopharmaceutical royalty investment company that provides funding to life sciences companies, academic institutions, and other organizations in exchange for rights to future payments tied to approved or development-stage medicines. Its business model gives innovators access to capital while allowing Royalty Pharma to participate in the long-term commercial success of pharmaceutical products.

The company acquires and manages royalty interests across a broad range of therapeutic areas, including immunology, oncology, neuroscience, rare diseases, and infectious diseases.